Akifumi Morinaka, CEO of Rege Nephro Co., Ltd. (Headquarters: Kyoto, Japan), participated in the roundtable hosted by Bayer Yakuhin Ltd. on September 3, 2025, titled “Shaping the Future of Drug Discovery in Japan: Bayer’s ‘Co-Creation’ Model – Bayer Co.Lab Open Innovation.”

In June 2025, Rege Nephro was selected as one of only two companies worldwide—and the sole representative from Japan—together with Switzerland-based NXI Therapeutics, to join the expanded program “Bayer Co.Lab Connect”, launched by Bayer to build a global innovation network.

The roundtable was attended by Friedman Janus from Bayer, Germany (Head of Regional Business Development and Bayer Co.Lab, Pharmaceuticals), and Nobuhiro Kazama from Bayer Yakuhin Ltd. (Executive Officer, Head of Business Development Division), who exchanged views on Bayer’s co-creation model and open innovation strategy.

At the event, Akifumi Morinaka shared concrete examples of the challenges Rege Nephro faces in globalization, and explained how participation in the Bayer Co.Lab program has contributed to overcoming these challenges. He emphasized the significant support received through the program, including expert advice and mentoring from Bayer specialists, as well as introductions to prominent U.S. investors.

Going forward, Rege Nephro will continue to leverage the valuable network and insights gained through Bayer Co.Lab Connect to accelerate research and development in its current pipeline and actively promote its expansion in global markets.

Media Inquiries:
Mariko Iwamura　
Rege Nephro Co., Ltd.
TEL: +81-75-744-6858
E-mail: info@regenephro.co.jp